dual dopamine D2/5-HT2a antagonists (LITMUS Molecular Design)

N/A

Report date: 2025/06/11 20:01:15
NME

Base Information

Drug Namedual dopamine D2/5-HT2a antagonists (LITMUS Molecular Design)
Drug Alias NameLMD-00100tLMD-00102tLMD-00060LMD-00076LMD-00094 +[13
ClassificationSmall molecules
Mechanisms of ActionSerotonin 2a (5-HT2a) receptor antagonistsDopamine D2 receptor antagonists
TargetsDopamine D2 receptorSerotonin 2a (5-HT2a) receptor
Therapy Area/IndicationsPsychotic Disorders
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesLITMUS Molecular Design LLC
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesLITMUS Molecular Design LLC
Active IndicationsN/A
Inactive IndicationsPsychotic Disorders

Other Information

ATC CodeN/A
Related LinksN/A